PPARG and breast carcinoma: In light of previous reports that Heregulin plays a causal role in Tamoxifen- and Gefitinib-resistant breast cancer [105], Park's work provides evidence that combination therapy with Heregulin and PPARγ-activators may be a novel strategy for the treatment of resistant or refractory breast cancer [44].